Potential increased risk of lower limb amputation with canaglifozin

An ongoing clinical study involving the type 2 diabetes drug canagliflozin (Invokana) has identified a potential increased risk of lower limb amputations. The medicine used to lower blood glucose in adult patients with type 2 diabetes has shown a two-fold higher incidence of lower limb amputations, primarily of the toes in the CANagliflozin cardioVascular Assessment Study (CANVAS). ...

Already a member?

Login to keep reading.

© 2021 the limbic